使用帕博利珠单抗治疗三阴性乳腺化生性癌的完全缓解
Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab.
作者信息
Ladwa Amrita, Elghawy Omar, Schroen Anneke, Abernathy Kristan, Schlefman Jenna, Dillon Patrick
机构信息
Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Department of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Case Rep Oncol. 2023 Oct 16;16(1):1129-1135. doi: 10.1159/000534146. eCollection 2023 Jan-Dec.
Metaplastic breast cancer (MpBC) is a rare form of breast malignancy with a poor prognosis and limited treatment guidance. Here, we report on a case of triple-negative MpBC that was successfully treated following the Keynote-522 clinical algorithm using pembrolizumab, paclitaxel, carboplatin, adriamycin, and cyclophosphamide in a neo-adjuvant fashion. The radiographic and histologic findings of the tumor are reviewed here along with the treatment regimen and response. No major toxicities associated with pembrolizumab were observed in this case. This case report serves as an example of complete pathological response of triple-negative MpBC with pembrolizumab plus chemotherapy and demonstrates the need for further research on chemoimmunotherapy for MpBC.
化生性乳腺癌（MpBC）是一种罕见的乳腺恶性肿瘤，预后较差且治疗指导有限。在此，我们报告一例三阴性MpBC病例，该病例采用帕博利珠单抗、紫杉醇、卡铂、阿霉素和环磷酰胺进行新辅助治疗，成功遵循了Keynote-522临床方案。本文回顾了肿瘤的影像学和组织学检查结果以及治疗方案和反应。该病例未观察到与帕博利珠单抗相关的重大毒性反应。本病例报告作为三阴性MpBC通过帕博利珠单抗联合化疗实现完全病理缓解的一个实例，并证明了对MpBC化疗免疫疗法进行进一步研究的必要性。
Zotero 插件